Patents by Inventor Richard A. Bergs

Richard A. Bergs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5510418
    Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.
    Type: Grant
    Filed: November 3, 1993
    Date of Patent: April 23, 1996
    Assignee: Collagen Corporation
    Inventors: Woonza M. Rhee, Richard A. Berg
  • Patent number: 5510121
    Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carders to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: April 23, 1996
    Inventors: Woonza M. Rhee, Richard A. Berg
  • Patent number: 5476666
    Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: December 19, 1995
    Assignee: Collagen Corporation
    Inventors: Woonza M. Rhee, Richard A. Berg
  • Patent number: 5475052
    Abstract: The present invention discloses collagen-synthetic polymer matrices which are prepared using a multiple step reaction. The first step of the reaction generally involves reacting collagen with a functionally activated synthetic hydrophilic polymer to form a collagen-synthetic polymer matrix. The synthetic hydrophilic polymer may be mono- or multifunctionally activated, but is preferably difunctionally activated, resulting in the formation of a crosslinked collagen matrix. The second step comprises modifying the collagen-synthetic polymer matrix according to one or more of the following methods: further crosslinking the matrix using a multifunctionally activated synthetic polymer, conjugating the matrix using a monofunctionally activated synthetic polymer, coupling biologically active molecules or glycosaminoglycans to the matrix, crosslinking the matrix using conventional chemical crosslinking agents, or modifying the collagen in the matrix by means of various chemical reactions.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: December 12, 1995
    Assignee: Collagen Corporation
    Inventors: Woonza M. Rhee, Richard A. Berg
  • Patent number: 5470911
    Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: November 28, 1995
    Assignee: Collagen Corporation
    Inventors: Woonza M. Rhee, Richard A. Berg
  • Patent number: 5196196
    Abstract: A method of treating wound healing with a composition containing protease nexin-I (PN-I) is disclosed. Compositions comprised of PN-I uniformly dispersed throughout a pharmaceutically acceptable carrier are disclosed as are such compositions further comprising antibiotics. Wound dressings are taught which are comprised of a support base having an absorbent area thereon which has PN-I absorbed thereon and which absorbent area is surrounded by a pressure sensitive adhesive strip for adhering the dressing to a surface surrounding the wound to be treated.
    Type: Grant
    Filed: January 16, 1992
    Date of Patent: March 23, 1993
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Randy W. Scott, Richard A. Berg
  • Patent number: 5112608
    Abstract: A method of treating wound healing with a composition containing protease nexin-I (PN-I) is disclosed. Compositions comprised of PN-I uniformly dispersed throughout a pharmaceutically acceptable carrier are disclosed as are such compositions further comprising antibiotics. Occlusive wound dressings are taught which are comprised of a support surface having an absorbent area thereon which has PN-I absorbed thereon and which absorbent area is surrounded by a pressure sensitive adhesive strip for adhering the dressing to a surface surrounding the wound to be treated.
    Type: Grant
    Filed: April 5, 1990
    Date of Patent: May 12, 1992
    Assignee: Incyte Pharmaceuticals
    Inventors: Randy W. Scott, Richard A. Berg
  • Patent number: 4997753
    Abstract: Weighted collagen microsponges having a highly crosslinked collagen matrix are described suitable for use in culturing organisms in motive reactor systems. The microsponges have an open to the surface pore structure, and pore sizes and volumes suitable for immobilizing a variety of bioactive materials. The microsponges also have an average particle size in the range of about 100 to about 1000 microns and a specific gravity above about 1.05.
    Type: Grant
    Filed: August 14, 1989
    Date of Patent: March 5, 1991
    Assignee: Verax Corporation
    Inventors: Robert C. Dean, Jr., Frederick H. Silver, Richard A. Berg, Philip G. Phillips, Peter W. Runstadler, Jr.
  • Patent number: 4971954
    Abstract: Stabilized collagen-based matrices are prepared by non-enzymatic glycosylation of native collagen to irreversibly cross-link collagen polypeptide chains. The sugar cross-linking agents, preferably is D-ribose, provide non-immunogenic, non-toxic cross-linked collagen matrices especially useful in clinical and veterinary applications.
    Type: Grant
    Filed: November 23, 1988
    Date of Patent: November 20, 1990
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Barbara Brodsky, Richard A. Berg, Gad Avigad, Eric Eikenberry, Manoj Jain, Shizuko Tanaka
  • Patent number: 4970298
    Abstract: This invention relates to a biodegradable collagen matrix having a pore size and morphology which enhances the healing of a wound. It further relates to a process for preparing the matrix. One embodiment of the invention comprises a biodegradable matrix which comprises collagen, hyaluronic acid and fibronectin. Other embodiments include a process which comprises freeze drying a dispersion containing collagen, crosslinking the collagen via two crosslinking steps and freeze drying the crosslinked matrix.
    Type: Grant
    Filed: June 18, 1986
    Date of Patent: November 13, 1990
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Frederick H. Silver, Richard A. Berg, Charles J. Doillon, Kevin Weadock, Conrad Whyne
  • Patent number: 4925924
    Abstract: A therapeutic method for treating pressure ulcers like decubitus ulcers with biodegradable collagen flake compositions and with biodegradable collagen sponge or sponge-like compositions. The products of the invention includes biodegradable collagen flake compositions and biodegradable collagen sponge or sponge-like compositions. The products are useful for medical applications, like skin reconstruction, treatment of wounds, especially deep wounds, also in connection with surgery, including cosmetic surgery. The invention also deals with biocompatible synthetic resin sponge or sponge-like and flake products for medical and similar applications. The invention contemplates the treatment of human and animal species.
    Type: Grant
    Filed: October 26, 1987
    Date of Patent: May 15, 1990
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Frederick H. Silver, Richard A. Berg, charles J. Doillon, Arkady Chernomorsky, Robert M. Olson
  • Patent number: 4863856
    Abstract: Weighted collagen microsponges having a highly crosslinked collagen matrix are described suitable for use in culturing organisms in motive reactor systems. The microsponges have an open to the surface pore structure, and pore sizes and volumes suitable for immobilizing a variety of bioactive materials. The microsponges also have an average particle size in the range of about 100 to about 1000 microns and a specific gravity above about 1.05.
    Type: Grant
    Filed: November 18, 1986
    Date of Patent: September 5, 1989
    Assignee: Verax Corporation
    Inventors: Robert C. Dean, Jr., Frederick H. Silver, Richard A. Berg, Philip G. Phillips, Peter W. Runstadler, Jr., Gennaro J. Maffia
  • Patent number: 4861714
    Abstract: Weighted collagen microsponges having a highly crosslinked collagen matrix are described suitable for use in culturing organisms in motive reactor systems. The microsponges have an open to the surface pore structure, and pore sizes and volumes suitable for immobilizing a variety of bioactive materials. The microsponges also have an average particle size in the range of about 100 to about 1000 microns and a specific gravity above about 1.05.
    Type: Grant
    Filed: April 4, 1985
    Date of Patent: August 29, 1989
    Assignee: Verax Corporation
    Inventors: Robert C. Dean, Jr., Frederick H. Silver, Richard A. Berg, Philip G. Phillips, Peter W. Runstadler, Jr.
  • Patent number: 4841962
    Abstract: A wound dressing comprising a crosslinked collagen matrix; a bioabsorbable adhesive coated on one surface of the collagen matrix; a multilayer polymer film imparting pre-selected moisture vapor and gas transmissivity to the dressing, secured to the opposite surface of the collagen matrix; and an adhesive securing the collagen matrix to the polymer film.
    Type: Grant
    Filed: September 11, 1987
    Date of Patent: June 27, 1989
    Inventors: Richard A. Berg, Frederick H. Silver, James M. Pachence, John D'Antonio
  • Patent number: 4837285
    Abstract: Collagen-based compositions for augmenting soft tissue, wound dressings, implants, injectable formulations or other drug delivery systems, comprising resorbable collagen matrix beads, the beads having an average pore size of from 50 to 350 microns, and the collagen comprising from 1 to 30% by volume of the beads, the collagen matrix being sufficiently open to stimulate cellular ingrowth therethrough and yet sufficiently stiff and non-compressible to fill and protect a wound, and the formulation being sufficiently moisture and gas permeable to prevent liquid pooling on a wound and to permit sufficient oxygen diffusion for promoting wound healing.
    Type: Grant
    Filed: September 8, 1987
    Date of Patent: June 6, 1989
    Assignee: MediMatrix
    Inventors: Richard A. Berg, Frederick H. Silver, James M. Pachence
  • Patent number: 4703108
    Abstract: There are disclosed processes for preparing biodegradable collagen-based matrices in sponge or sheet form wherein in one embodiment a collagen-based material including a collagen selected from the group consisting of types I, II and II collagens is freeze dried to form a collagen-based sponge which is contacted with a cross-linking agent selected from the group consisting of a carbodiimide or a succinimidyl active ester to form an intermediate collagen-based matrix which is subsequently subjected to conditions of severe dehydration to form the collagen-based matrix in sponge or sheet form. In another embodiment, a collagen-based sponge or sheet is first subjected to conditions of severe dehydration followed by contacting the thus formed intermediate collagen-based matrix with a carbodiimide crosslinking compound to form the collagen-based matrix in sponge or sheet form.
    Type: Grant
    Filed: March 26, 1986
    Date of Patent: October 27, 1987
    Assignee: University of Medicine & Dentistry of New Jersey
    Inventors: Frederick A. Silver, Richard A. Berg, David E. Birk, Kevin Weadock, Conrad Whyne
  • Patent number: 4404549
    Abstract: Mounted on a housing, which is adapted to be carried on the belt of an operator, is a manually activated alarm switch. In the event of an emergency, the operator activates the alarm switch to set off an alarm contained in the housing. The alarm switch is reset upon release. However, the alarm continues to operate until deactivated by a key switch. Formed in the housing is a suitable key slot for receiving a preselected key. The rotation of the preselected key in the key slot serves to deactivate the alarm.
    Type: Grant
    Filed: May 11, 1981
    Date of Patent: September 13, 1983
    Inventor: Richard Berg